Press Releases

Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

 Nov 14, 2022, 07:30 ET  Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Size of 350 patients Topline Results Currently Expected Second Quarter Calendar 2023 Vyleesi® – Net Product Revenue Increased 13% and Prescriptions Dispensed Increased 17%, Over the Prior Quarter Prescription Refills Exceed 50% …

Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update Read More »

Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022

 Nov 09, 2022, 17:16 ET  CRANBURY, N.J., Nov. 9, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2023 operating results on Monday, November 14, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive …

Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022 Read More »

Palatin Announces $10 Million Registered Direct Offering

 Oct 31, 2022, 09:30 ET  CRANBURY, N.J., Oct. 31, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and …

Palatin Announces $10 Million Registered Direct Offering Read More »

Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting

 Oct 24, 2022, 17:32 ET  Preclinical data shows efficacy in animal models of ulcerative colitis Human pharmacokinetic data show oral formulation releases PL8177 in colon CRANBURY, N.J., Oct. 24, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor …

Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting Read More »

First Patient Enrolled in Palatin’s Phase 2 study of PL8177 in Ulcerative Colitis Trial

 Oct 20, 2022, 07:30 ET  Oral PL8177 may provide an effective, safe, and tolerable treatment option for ulcerative colitis patients prior to being treated with immunosuppressive therapies, which have significant safety and tolerability concerns Primary endpoint is the Mayo Endoscopic Subscore, which evaluates the level of disease in the colon mucosa Interim data currently expected …

First Patient Enrolled in Palatin’s Phase 2 study of PL8177 in Ulcerative Colitis Trial Read More »

Palatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD)

 Oct 17, 2022, 07:30 ET  Peer-reviewed paper presents notable mechanism of action findings Bremelanotide significantly increased sexual desire for up to 24 hours post administration CRANBURY, NJ, Oct. 17, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor …

Palatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD) Read More »

Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results

 Oct 13, 2022, 07:30 ET  Net product revenue for prescriptions dispensed increased 20% Prescriptions dispensed increased 17%, over prior quarter Refills accounted for over 50% of prescriptions dispensed CRANBURY, N.J., Oct. 13, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of …

Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results Read More »

Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference

 Sep 29, 2022, 15:45 ET  Overview of Development Pipeline of Melanocortins for Treatment of Ocular Conditions and Role in Resolving Inflammation PL9643 Phase 3 Study Results in Dry Eye Disease Currently Expected 2Q 2023 Palatin Progressing Development Programs in Retinal and Front-of-the-Eye Indications Supported by Breakthrough Science CRANBURY, N.J., Sept. 29, 2022 /PRNewswire/ — Palatin …

Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference Read More »

Palatin to Participate in Ladenburg Thalmann Healthcare Conference

 Sep 29, 2022, 13:31 ET  CRANBURY, N.J., Sept. 29, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that the Company will participate in the Ladenburg Thalmann Healthcare Conference on September 29, 2022. Carl Spana, …

Palatin to Participate in Ladenburg Thalmann Healthcare Conference Read More »

Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update

 Sep 22, 2022, 07:30 ET  Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Sample Size of 350 Patients Topline Results Currently Expected Second Quarter Calendar 2023 Vyleesi® – Gross product sales increased 79%, net product revenue increased 257% and prescriptions dispensed increased 49%, …

Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update Read More »

Scroll to Top